The decision to register the therapy was supported by data from the Phase III TRAILBLAZER-ALZ 2 and TRAILBLAZER-ALZ 6 trials.

The Tobias and Lechleiter families donated $20 million to establish the Institute for Clinical Innovation at IU Health, the largest gift in its history.